Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Spero Therapeutics, Inc. (SPRO) had Consolidated Net Income/Loss of $-7.38M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$5.44M |
|
$-7.38M |
|
-- |
|
$5.44M |
|
$13.36M |
|
$-7.92M |
|
$0.53M |
|
$-7.38M |
|
$-7.38M |
|
$-7.38M |
|
$-7.38M |
|
|
Consolidated Net Income/Loss |
$-7.38M |
$-7.38M |
|
$-7.92M |
|
$-7.92M |
|
56.28M |
|
56.28M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$52.32M |
|
-- |
|
$1.85M |
|
$54.17M |
|
$13.65M |
|
-- |
|
$14.03M |
|
$27.68M |
|
$26.49M |
|
$26.49M |
|
$26.49M |
|
56.31M |
|
| Cash Flow Statement Financials | |
$-4.27M |
|
-- |
|
-- |
|
$52.89M |
|
$48.62M |
|
$-4.27M |
|
$3.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-145.46% |
|
-145.46% |
|
-- |
|
-135.65% |
|
-135.65% |
|
$-4.27M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
2.21 |
|
40.67 |
|
-27.86% |
|
-27.86% |
|
-13.63% |
|
-27.86% |
|
$0.47 |
|
$-0.08 |
|
$-0.08 |
|